Palisade Capital Management’s Novartis NVS Stock Holding History

Palisade Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,282	Closed	-$238K	–	465
2018 Q1	$238K	Sell	3,282 -352	-10%	-$26.8K	0.01%	421
2017 Q4	$273K	Sell	3,634 -279	-7%	-$21.1K	0.01%	405
2017 Q3	$301K	Hold	3,913	–	–	0.01%	387
2017 Q2	$293K	Hold	3,913	–	–	0.01%	405
2017 Q1	$260K	Sell	3,913 -11	-0.3%	-$733	0.01%	403
2016 Q4	$256K	Sell	3,924 -363	-8%	-$23.5K	0.01%	441
2016 Q3	$303K	Hold	4,287	–	–	0.01%	521
2016 Q2	$317K	Buy	4,287 +179	+4%	+$12.4K	0.01%	496
2016 Q1	$267K	Sell	4,108 -61	-1%	-$4.15K	0.01%	505
2015 Q4	$321K	Buy	4,169 +770	+23%	+$61.2K	0.01%	489
2015 Q3	$280K	Buy	3,399 +279	+9%	+$24.8K	0.01%	496
2015 Q2	$275K	Hold	3,120	–	–	0.01%	502
2015 Q1	$276K	Buy	3,120 +279	+10%	+$24.7K	0.01%	480
2014 Q4	$236K	Hold	2,841	–	–	0.01%	460
2014 Q3	$240K	Hold	2,841	–	–	0.01%	466
2014 Q2	$230K	Buy	+2,841	New	+$223K	0.01%	459

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Palisade Capital Management's NVS Position: Q2 2018 in Review

Palisade Capital Management sold out of Novartis (NVS) in Q2 2018, closing a stake of 3,282 shares — an estimated $238K sold.

Palisade Capital Management first reported a position in NVS in Q2 2014 and held it in 16 quarters. The position peaked at $321K in Q4 2015. 987 funds tracked by Wall St. Rank hold NVS as of Q2 2018.

Palisade Capital Management reported no remaining Novartis position as of Q2 2018 after selling out during the quarter.
Palisade Capital Management sold 3,282 Novartis shares in Q2 2018, an estimated $238K.
Palisade Capital Management first reported a position in Novartis in Q2 2014 and held it in 16 quarters.
Palisade Capital Management's Novartis position peaked at $321K in Q4 2015.
987 funds tracked by Wall St. Rank held Novartis as of Q2 2018.

Based on Palisade Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.